Kamath brings over three decades of leadership experience in healthcare, spanning pharmaceuticals, over-the-counter (OTC) products and diagnostics
Plasmagen Biosciences, a biopharmaceutical company focused on blood plasma-derived pharmaceutical products for India and emerging markets, announced the appointment of Vivek V Kamath as its Chief Executive Officer, with effect from October 6, 2025. Kamath brings over three decades of leadership experience in healthcare, spanning pharmaceuticals, over-the-counter (OTC) products and diagnostics. His experience extends across geographies like India, South Asia and Southeast Asia where he has held senior leadership roles, including serving as the Managing Director of Abbott India, Abbott Healthcare and MSD Pharmaceuticals (South Asia). Kamath has also been a strategic advisor to leading private equity funds, supporting the growth of their healthcare portfolio companies.
“Plasmagen’s mission is to become a trusted and leading Indian biopharmaceutical company that improves the health and quality of life of patients globally. Kamath’s deep experience in leading large organisations, coupled with his operational expertise and ability to build world-class teams, makes him an outstanding addition to our leadership team,” said Vinod Nahar, Founder and Executive Chairman, Plasmagen Biosciences. “With Kamath’s appointment as CEO, I will step into the Executive Chairman role steering Plasmagen’s long-term strategy. I look forward to working alongside him as we build India’s premier fully integrated plasma products company.”
Kamath said, “Plasmagen’s combination of world-class manufacturing and a purpose-driven leadership team has created a remarkable foundation for growth. I am privileged to join the company at this pivotal stage and look forward to working with Vinod and our colleagues in shaping the next chapter—anchored in innovation, quality, and care that reaches patients globally.”
